G
Genmab
Biotech & Life Sciences · Copenhagen, Denmark · Founded 1999 · IPO 2000 Decacorn
Investors
6 investors on Genmab's cap table
Sourced from Dealroom's funding history.
Ownership
Who owns Genmab
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (May/2026). Percentages are indicative.
“Other / undisclosed” is the 92.5% not attributed to a named shareholder. See the full cap table on Dealroom →
Global footprint
Where Genmab has talent and traffic
team presence
across markets
Talent graph
The shape of Genmab's talent
Dealroom maps Genmab's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.
Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.
Patent intelligence
$328M patent portfolio · 202 active families
Where Genmab concentrates vs peers
Each axis is a top-10 topic across Genmab and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Capital deployed
Genmab's 2 investments and acquisitions.
Every disclosed deal where Genmab appeared as a backer or acquirer, 2024–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
2 deals across Genmab's capital deployment.
Where the deals concentrate by sector, stage, and decade.
02 · Portfolio market map
Genmab's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
What the market is saying about Genmab
An AI-synthesized read of the highest-engagement posts about Genmab on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genmab on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.